Hua Medicine grants 20m share options to boost performance

Hua Medicine announced on November 28, 2025, the grant of 20,000,000 share options to three executive directors and 71 employees. These options, granted under the company's share option scheme, allow grantees to subscribe for new shares at an exercise price of HK$3.38 per share. The purpose of these grants is to recognize outstanding performance and reinforce long-term commitment.

The share options have a validity period of ten years and vest in three tranches: 30% on May 1, 2027, 30% on May 1, 2028, and 40% on May 1, 2029. Vesting is contingent upon the achievement of performance targets by both the individual grantees and the company. The company's revenue targets for the financial years ending December 31, 2026, 2027, and 2028 are RMB900 million, RMB1,350 million, and RMB1,800 million, respectively.

Three executive directors received a total of 4,800,000 share options: Dr. Li Chen (3,400,000), Mr. George Chien Cheng Lin (500,000), and Ms. Yi Zhang (900,000). The remaining 15,200,000 share options were granted to other employees. Following this grant, 15,107,033 shares remain available for future grant under the scheme mandate.